Immunotherapy of Myeloma- T-cell Engagement
In the final session of Myeloma2018, James Kochendorfer, MD, Adam Cohen, MD, Yi Lin, MD, PhD, Krina Patel, MD, MSc, and Hermann Einsele, MD, share key findings on novel targets for CAR T-cell therapy and bi-specific antibodies in MM. Exciting clinical trial updates are presented in this session, drawing attention to BCMA and SLAMF7 as potential therapeutic targets for CAR T-cell therapy.
Presentations
National Cancer Institute, Bethesda, MD
James Kochendorfer, MD, from the National Cancer Institute, Bethesda, MD, discusses BCMA CAR T-cell therapy.
University of Pennsylvania, Philadelphia, PA
Adam Cohen, MD, from the University of Pennsylvania, Philadelphia, PA, talks about the University of Penn experience.
Mayo Clinic, Rochester, MN
Yi Lin, MD, PhD, from the Mayo Clinic, Rochester, MN, summarizes the industry clinical trials involving BCMA.
MD Anderson Cancer Center, Houston, TX
Krina Patel, MD, from the MD Anderson Cancer Center, Houston, TX, explores SLAMF7 CAR T-cell therapy.
University Hospital Würzburg, Würzburg, Germany
Hermann Einsele, MD, from the University Hospital Würzburg, Würzburg, Germany, speaks on BiTEs in multiple myeloma.
